Search Results - "Eek, Richard Wilhelm"

Risk assessment model potency to detect patients most likely to benefit from thromboprophylaxis: An application of the TARGET-TP score by Burbury, Kate, Alexander, Marliese, Harris, Samuel J., Underhill, Craig, Torres, Javier, Sharma, Sharad, Lee, Nora, Wong, Hui-Li, Eek, Richard Wilhelm, Michael, Michael, Tie, Jeanne, Rogers, Jennifer, Heriot, Alexander Graham, Ball, David, MacManus, Michael Patrick, Wolfe, Rory, Solomon, Benjamin J.

“…12116 Background: Interventional trials applying risk models for targeted-thromboprophylaxis (TP) for ambulatory cancer patients have previously excluded low…”
Get full text

Awareness, preferences, and experiences of thrombosis and thromboprophylaxis in adults commencing systemic anticancer therapies: TARGET-TP trial by Alexander, Marliese, Harris, Samuel John, Torres, Javier, Underhill, Craig, Sharma, Sharad, Lee, Nora, Wong, Hui-Li, Eek, Richard Wilhelm, Michael, Michael, Tie, Jeanne, Rogers, Jennifer, Patrick, Rachael, Heriot, Alexander Graham, Ball, David, MacManus, Michael Patrick, Wolfe, Rory, Solomon, Benjamin J., Burbury, Kate

“…e24129 Background: While a leading cause of morbidity and mortality in cancer, prior studies report low awareness of cancer-associated thrombosis (CAT) among…”
Get full text

Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens by Lu, Janice M., Kalinsky, Kevin, Tripathy, Debu, Sledge, George W., Gradishar, William John, O'Regan, Ruth, O'Shaughnessy, Joyce, Modi, Shanu, Park, Haeseong, McCartney, Amelia, Frentzas, Sophia, Shannon, Catherine M., Eek, Richard Wilhelm, Martin, Miguel, Curigliano, Giuseppe, Jerusalem, Guy Heinrich Maria, Huang, Chiun-Sheng, Press, Michael F., Tolaney, Sara M., Hurvitz, Sara A.

“…TPS1112 Background: The overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) occurs in approximately 20% of breast cancers…”
Get full text

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials by Hurvitz, Sara A., Park, Haeseong, Frentzas, Sophia, Shannon, Catherine M., Cuff, Katharine, Eek, Richard Wilhelm, Budd, George Thomas, McCartney, Amelia, O'Shaughnessy, Joyce, Lu, Janice M., Zhang, Jian, Ji, Dongmei, Shen, Weina, Li, Matt, Yan, Jinchun, Xia, Gang, Ji, Yanping, Yao, Sulan, Xiong, Gaozhun, Hu, Xichun

“…Abstract only 1038 Background: ARX788 is a site-specific, homogeneous, and highly stable ADC. The payload AS269 is conjugated to the synthetic amino acids…”
Get full text

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand by Quach, Hang, Lasica, Masa, Routledge, David, Kalff, Anna, Lim, Andrew, Low, Michael, Estell, Jane A., Sidiqi, M Hasib, Campbell, Philip, Eek, Richard Wilhelm, Lai, Hock C., McCaughan, Georgia J., D'Rozario, James, Browlett, Peter, Rajagopal, Rajeev, Heenan, Jessica, Murphy, Nicholas E, Renwick, William, Huan, Georgina, Mollee, Peter

“…Abstract only TPS8055 Background: Len maintenance post ASCT is standard of care for patients (pts) with NDMM. Deep responses (CR or better) post ASCT…”
Get full text